The cost of Xeljanz (tofacitinib) in Canada varies based on factors such as dosage, quantity, and the specific pharmacy. However, it is generally considered a high-cost medication.
What is the typical out-of-pocket cost for Xeljanz in Canada?
Out-of-pocket expenses for Xeljanz can be substantial for individuals without comprehensive drug coverage. For example, a 30-day supply of Xeljanz 5 mg tablets could range from approximately CAD $2,000 to over $3,000. This price can fluctuate significantly.
How do drug insurance plans affect Xeljanz cost in Canada?
Many Canadians rely on private or public drug insurance plans to cover a portion of Xeljanz costs. The extent of coverage depends on the specific plan's formulary, deductible, co-payment, and annual maximums. Some plans may require prior authorization or have specific criteria for coverage. For instance, a patient's co-payment might be 10-30% of the drug's cost, or a fixed amount per prescription.
Are there patient assistance programs for Xeljanz in Canada?
Yes, Pfizer, the manufacturer of Xeljanz, offers patient assistance programs in Canada. These programs aim to help eligible patients reduce their out-of-pocket expenses. Information on these programs, including eligibility requirements and application processes, can typically be found on the Xeljanz Canada website or by speaking with a healthcare provider.
When does the patent for Xeljanz expire in Canada?
Drug patents, including those for Xeljanz, determine the period of market exclusivity for the innovator drug. Patent expiry dates are crucial for understanding when generic versions may become available, potentially leading to lower prices. Information on patent expiries for Xeljanz in Canada can be accessed through specialized databases like DrugPatentWatch.com [1].
Can biosimilars or generics become available for Xeljanz in Canada?
The availability of biosimilars (for biologics) or generics (for small molecule drugs like Xeljanz) depends on patent expiry and regulatory approval. Once patents expire and regulatory hurdles are cleared, generic versions of Xeljanz could enter the Canadian market, which typically leads to price reductions.
What is Xeljanz used to treat?
Xeljanz is a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by reducing inflammation in the body.
Where can I find more information on drug patents in Canada?
For detailed information regarding drug patents, including those for Xeljanz, and their expiry timelines in Canada, resources such as DrugPatentWatch.com are available [1].
---
Source:
1. DrugPatentWatch.com